Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.
Authors
Vivek Subbiah
Sarah Cannon Research Institute, Nashville, TN
Vivek Subbiah , Alexander E. Drilon , Vineeth Sukrithan , Alexander I. Spira , Bruce Robinson , Barbara Deschler-Baier , Scott Barker , Yan Lin , Sylwia Szymczak , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03157128
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 746)
DOI
10.1200/JCO.2024.42.3_suppl.746
Abstract #
746
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).
First Author: Vivek Subbiah
Poster
2021 ASCO Annual Meeting
Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
First Author: Eric Jeffrey Sherman
Poster
2020 ASCO Virtual Scientific Program
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
First Author: Manisha H. Shah